Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

63 results about "Ketorolac Tromethamine" patented technology

The tromethamine salt of ketorolac, a synthetic pyrrolizine carboxylic acid derivative with anti-inflammatory, analgesic and antipyretic properties. Ketorolac tromethamine, a non-selective inhibitor of the cyclooxygenases (COX), inhibits both COX-1 and COX-2 enzymes. This agent exerts its anti-inflammatory effect by preventing conversion of arachidonic acid to prostaglandins at inflammation site mediated through inhibition of COX-2, which is undetectable in most tissues but is up-regulated at the inflammation sites. Since COX-1 is expressed virtually in all tissues, inhibition of COX-1 enzyme by this agent prevents normal state production of prostaglandins, which plays housekeeping roles in the protection of the gastrointestinal tract, regulating renal blood flow, and functioning in platelet aggregation. As a result, inhibition of COX-1 is usually associated with adverse effects such as gastrointestinal toxicity and nephrotoxicity.

Ketoralac ammonia butanetriol injection and preparing method thereof

Disclosed is ketorolac tromethamine, which is a pyrrole acid derivative developed by the Syntex company in the U.S. The invention can effectively inhibit prostaglandin (PG) from synthesizing with functions of analgesia, anti-inflammation, antipyresis and inhibiting the platelets from aggregating. The invention provides a preparation method of ketorolac tromethamine injection, which well improves the stability and the clarity of the preparation with stable process.
Owner:鲁南新时代生物技术有限公司

Ketorolac tromethamine nasal spray

InactiveCN103285472AReduced filling equipment requirementsIncrease shipmentsPharmaceutical containersMedical packagingMedicineNasal spray
The invention provides a ketorolac tromethamine nasal spray. A spraying device comprises a spraying bottle and a spraying head, and is characterized in that the spraying bottle comprises a casing (1) and a liner (2) with the volume of 1.5 ml; the liner of the spraying bottle is in a shape of a cylinder, the combination of a cylinder and a cone, or the combination of a cylinder, a cone and a cylinder with a smaller diameter ; the casing of the spraying bottle has the same appearance, size and connector part as those of a conventional 10 ml spray sold in the market; and the spraying head adopts a praying head of the conventional 10 ml spray sold in the market. The ketorolac tromethamine nasal spray has the advantages of few residues, high safety and multiple effective spraying times, the production cost can be reduced, and the medicine waste is prevented.
Owner:北京天衡药物研究院有限公司

Preparation method of ketorolac tromethamine

The invention provides a preparation method of ketorolac tromethamine. 5-benzoyl-2, 3-dihydro-1H-dilazine-1 and 1-diethyl azodicarboxylate are the starting materials and are prepared into salt by alkaline hydrolysis and acidification when reducers exist, and finally, the salt is prepared into ketorolac tromethamine. The method does not need complicated decarboxylation process, and effectively solves the problems of low purity, poor color and the like caused by the oxidizability of ketorolac. The invention has the advantages of simple operation, high yield and high purity (the total yield in two steps reaches 95% and the purity reaches more than 99.9%); thus, the preparation method is suitable for large-scale commercial process.
Owner:LUNAN PHARMA GROUP CORPORATION

Medical Kits

InactiveUS20150014211A1Surgical furnitureDispensing apparatusOffice practiceMedical treatment
Provided is a medical kit with all the necessary components for a medical practitioner in the office practice setting to inject a variety of anesthetics. The kits can comprise a holder, such as a box, and active pharmaceutical ingredients (API), with each API placed in a separate container in a form that is ready for injection, the API selected from the group consisting of: a. lidocaine hydrochloride and triamcinolone acetonide with or without a separate container of ammonia; b. bupivacaine hydrochloride (HCl) and lidocaine hydrochloride (HCl), and optionally one or more of triamcinolone acetonide, methylprednisolone acetate, or dexamethasone sodium; c. bupivacaine hydrochloride (HCl) and one or more of triamcinolone acetonide or methylprednisolone acetate; d. Methylprednnisolone acetate and lidocaine hydrochloride (HCl), and optionally bupivacaine hydrochloride (HCl); e. methylprednisolone acetate and lidocaine hydrochloride (HCl), and bupivacaine hydrochloride (HCl); f. lidocaine hydrochloride, triamcinolone acetonide, and ammonia; g. bupivacaine hydrochloride or lidocaine HCl, and betamethasone sodium phosphate and betamethasone acetate; h. bupivacaine hydrochloride or lidocaine HCl, and dexamethasone sodium phosphate; i. ketorolac tromethamine, lidocaine HCl, and optionally bupivacaine hydrochloride; and j. one or more of dexamethasone sodium.
Owner:ASCLEMED USA

Method for researching abirritation mechanism of Chinese herbal medicinal ingredients of Xinhuang tablets

The invention discloses a method for researching an abirritation mechanism of Chinese herbal medicinal ingredients of Xinhuang tablets and a pharmaceutical composition comprising the Xinhuang tablets. The method for researching the abirritation mechanism comprises the following steps of preparing a Xinhuang tablet sample and an indometacin sample in a weight ratio of 95:2, establishing a living acetic acid writhing reaction model and a living planta reaction model to evaluate the drug treatment effects and the synergic index of the Chinese herbal medicinal ingredients of the Xinhuang tablets and indometacin, and establishing a naloxone occlusion reaction model to evaluate the influence of occlusion on the analgesic effect. Based on the research on the mechanism of action, and in order to improve the treatment effect for analgesia, the invention also provides an analgesic composition which is composed of the Xinhuang tablets and ketorolac tromethamine. The method is used for measuring the abirritation mechanism of the Chinese herbal medicinal ingredients of the Xinhuang tablets, is simple and clear; applicable effective drugs can be selected from the known compound medicines by the pharmacological research method.
Owner:XIAMEN TRADITIONAL CHINESE MEDICINE

Compositions and Methods for Treating Eyes and Methods of Preparation

Pharmaceutical compositions, methods for treating various issues of the eyes, and methods of preparing such compositions are described. These pharmaceutical compositions may be for treating glaucoma, in preparation of eye surgery, during eye surgery, various post-op care (e.g., after cataract surgery, laser eye surgery, and the like), for treating dry eyes, and / or for promoting eyelash growth. These pharmaceutical compositions may comprise such active ingredients (APIs) as: timolol, latanoprost, brimonidine tartrate, dorzolamide, moxifloxacin HCl, dexamethasone PO4, phenylephrine HCl, lidocaine HCl, ketorolac tromethamine, bromfenac, prednisolone PO4, gatifloxacin, amniotic cytokine extract (ACE), prostaglandin E2 (PGE2), and combinations thereof.
Owner:OCULAR SCI INC

Nasal-delivery temperature-sensitive in-situ gel sustained-release preparation comprising ketorolac tromethamine

InactiveCN106309354AOvercoming the problem of dissolving too quicklyGood bioadhesionOrganic active ingredientsAntipyreticNasal cavityCarrageenan
The invention belongs to the field of medicine preparations and relates to a nasal-delivery temperature-sensitive in-situ gel sustained-release preparation comprising ketorolac tromethamine and a preparation method thereof. The preparation is composed of poloxamer, carrageenan and ketorolac tromethamine in effective dose. The preparation integrates reverse-phase gelatinization property of the poloxamer and the property that the carrageenan can significantly improve erosion of the temperature-sensitive gel, and improves retention effect of the poloxamer gel in nasal cavity and improves absorption of the ketorolac tromethamine. The preparation is improved in bioavailability of the ketorolac tromethamine through nasal delivery and improves patient compliance.
Owner:FUDAN UNIV

Analgesic formulations and methods for reduced postoperative nausea and vomiting and enhanced postoperative pain relief

A multimodal anti-emetic anesthetic / analgesic formulation for pain control not limited to postoperative pain control is described herein. The opioid-free / sparing anesthetic / analgesic formulation comprises a local anesthetic, an N-methyl-D-aspartate (NMDA) receptor antagonist, and a cyclooxygenase (COX) inhibitor such as Bupivacaine Hydrochloride, Ketamine Hydrochloride, and Ketorolac Tromethamine, which is effective to significantly reduce postoperative nausea and vomiting and enhance postoperative pain relief as compared to existing prior art anesthetics / analgesics. The formulation is administered to a mammal in need of anesthesia / analgesia and can be used as a preemptive and preventative multimodal analgesic. The formulation may have a buffer to enhance its shelf life and improve pharmacokinetics. The formulation may further comprise an alpha agonist, a steroid, a Transient Receptor Potential Channel agonist or antagonist, a beta-lactam antibiotic, a protein kinase inhibitor, a competitive or non-competitive glycine or glutamate antagonist, a glutamate or glycine inhibitor, a cyclooxygenase 3 inhibitor, or combinations thereof.
Owner:HUTCHISON HEALTH LLC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products